Appeal type: unknown
Decision: unknown

 
The rules say that plans must pay for a medical service or item if regular Medicare would pay for it in this case. 
You can find this rule at 42 Code of Federal Regulations (CFR) Section 422.101. 
 
 
  
  The rules state that therapeutic continuous glucose monitors (CGMs) and related supplies are covered by 
Medicare when all of the following coverage criteria are met: 
  1. The beneficiary has diabetes mellitus, 
  2. The beneficiary is insulin-treated with multiple (three or more) daily administrations of insulin or a 
       Medicare-covered continuous subcutaneous insulin infusion (CSII) pump, 
  3. The beneficiarys insulin treatment regimen requires frequent adjustment by the beneficiary on the basis of  
       blood glucose monitor (BGM) or CGM testing results, 
  4. Within six (6) months prior to ordering the CGM, the treating practitioner has an in-person visit with the  
       beneficiary to evaluate their diabetes control and determined that criteria (1-3) above are met; and, 
  5. Every six (6) months following the initial prescription of the CGM, the treating practitioner has an  
      in-person visit with the beneficiary to assess adherence to their CGM regimen and diabetes treatment plan. 
 
You can find this information in the Local Coverage Determination (LCD): Glucose Monitors (L33822). 
 
The rules state that Administration of continuous subcutaneous insulin for the treatment of diabetes mellitus 
(Refer to the ICD-10 code list in the LCD-related Policy Article for applicable diagnoses.) if criterion A or B is 
met and if criterion C or D is met: 
A. C-peptide testing requirement  must meet criterion 1 or 2 and criterion 3: 
              1.  C-peptide level is less than or equal to 110 percent of the lower limit of normal of the  
                   laboratory's measurement method. 
              2.  For beneficiaries with renal insufficiency and a creatinine clearance (actual or calculated from age,  
                   weight, and serum creatinine) less than or equal to 50 ml/minute, a fasting C-peptide level is less 
                   than  or equal to 200 per cent of the lower limit of normal of the laboratorys measurement 
                   method. 
              3.  A fasting blood sugar obtained at the same time as the C-peptide level is less than or equal to  
                   225 mg/dl. 
B. Beta cell autoantibody test is positive. 
C. The beneficiary has completed a comprehensive diabetes education program, has been on a program of 
             multiple daily injections of insulin (i.e., at least 3 injections per day) with frequent self-adjustments of  
             insulin dose for at least 6 months prior to initiation of the insulin pump, and has documented frequency 
             of glucose self-testing an average of at least 4 times per day during the 2 months prior to initiation of  
             the insulin pump, and meets one or more of the following criteria (1 - 5) while on the multiple injection 
             regimen: 
             1. Glycosylated hemoglobin level (HbA1C) greater than 7 percent 
             2. History of recurring hypoglycemia 
             3. Wide fluctuations in blood glucose before mealtime 
             4. Dawn phenomenon with fasting blood sugars frequently exceeding 200 mg/dL 
             5. History of severe glycemic excursions 
D. The beneficiary has been on an external insulin infusion pump prior to enrollment in Medicare and has  
            documented frequency of glucose self-testing an average of at least 4 times per day during the month 
             prior to Medicare enrollment. 
 
If criterion A or B is not met, the pump and related accessories, supplies, and insulin will be denied as not 
reasonable and necessary. If criterion C or D is not met, the pump and related accessories, supplies, and insulin 
will be denied as not reasonable and necessary. 
 
Continued coverage of an external insulin pump and supplies requires that the beneficiary be seen and 
evaluated by the treating practitioner at least every 3 months. In addition, the external insulin infusion pump 
must be ordered and follow-up care rendered by a practitioner who manages multiple beneficiaries on  
 
 continuous subcutaneous insulin infusion therapy and who works closely with a team including nurses, diabetic 
educators, and dieticians who are knowledgeable in the use of continuous subcutaneous insulin infusion 
therapy. 
 
Subcutaneous insulin is administered using ambulatory infusion pump E0784. Claims for usage of infusion 
pumps other than E0784 will be denied as not reasonable and necessary. 
 
You can find these rules in Local Coverage Determination (LCD) External Infusion Pumps (L33794). 
 
If you want to read these Medicare rules, you can go to this website www.medicareappeal.com.